In lung cancer, WDR4 degrades PML through the ubiquitination pathway and upregulates its downstream CD73, urokinase plasminogen activator receptor (uPAR) and serum amyloid A2 (SAA2) via HIF-1. Here, WDR4 is linked to lung cancer.